Free Newsletter
Sanofi dengue vax enters PhIII
Sanofi Pasteur's dengue vaccine has entered its first Phase III clinical study in Australia. The study is part of a global Phase III clinical study program aimed at advancing the development of a novel vaccine for the prevention of dengue disease in children and adults. Currently, there is no specific treatment available for dengue fever, which is a threat to nearly 3 billion people and a public health priority in many countries of Latin America and Asia where epidemics occur.
"To address the global health challenge represented by dengue fever, we are conducting an unprecedented dengue vaccine research and development program as well as a scale up of the vaccine production," says Wayne Pisano, president and CEO of Sanofi Pasteur. "We are now entering the final laps of a long run that Sanofi Pasteur started almost 20 years ago. If successful, we are committed to introducing the vaccine in countries where dengue is of highest public health priority."
- get the Sanofi release
Related Articles:
Inviragen starts Colombian Phase I dengue trial
Inviragen, PharmaJet land $15.5M for needle-free dengue vax
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: